Stay updated on Risankizumab Maintenance in Psoriasis Clinical Trial
Sign up to get notified when there's something new on the Risankizumab Maintenance in Psoriasis Clinical Trial page.

Latest updates to the Risankizumab Maintenance in Psoriasis Clinical Trial page
- Check2 days agoChange DetectedThe ClinicalTrials.gov footer revision label updates from v3.8.0 to v3.8.1, while the study record content remains unchanged.SummaryDifference0.0%

- Check9 days agoChange DetectedThe record now presents details of AbbVie’s completed Phase 3 risankizumab maintenance study for moderate-to-severe plaque psoriasis, including eligibility, treatment and outcomes, locations, publications, and study documents.SummaryDifference100%

- Check16 days agoChange DetectedThe site footer now identifies the platform as revision v3.8.0 instead of v3.7.2.SummaryDifference0.2%

- Check30 days agoChange DetectedA site-wide NIH banner announces a website transition and a terminology change from “Artificial Intelligence” to “Super Intelligence.” The site revision changed from v3.7.1 to v3.7.2, while the study page continues to display a 403 error.SummaryDifference1%

- Check44 days agoChange DetectedThe footer now displays revision v3.7.1 instead of v3.7.0.SummaryDifference0.2%

- Check58 days agoChange DetectedThe page now displays a 403 Forbidden error instead of the study record details, signaling restricted access to the content. Previous study content and related metadata are no longer visible.SummaryDifference17%

Stay in the know with updates to Risankizumab Maintenance in Psoriasis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Risankizumab Maintenance in Psoriasis Clinical Trial page.